Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Novel Bispecific Antibodies Increase    T-Cell Cytotoxicity against Pancreatic Cancer Cells

(2014) H.-H. Oberg et al.   CANCER RESEARCH

The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies

(2014) Mohsen Vosooghi et al.   Expert Opinion on Drug Discovery

Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma

(2014) Ole Helm et al.   PLoS One

Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties

(2013) Namita Kundu et al.   BREAST CANCER RESEARCH AND TREATMENT

The stromal compartments in pancreatic cancer: Are there any therapeutic targets?

(2013) Serena Lunardi et al.   CANCER LETTERS

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis

(2013) Xinrong Ma et al.   OncoImmunology

Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells

(2012) Ayano Kabashima-Niibe et al.   CANCER SCIENCE

Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development

(2012) R. Hill et al.   MOLECULAR CANCER THERAPEUTICS

Prostaglandin E2 and T cells: friends or foes?

(2011) Vinatha Sreeramkumar et al.   IMMUNOLOGY AND CELL BIOLOGY

PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling

(2010) Ludovic Martinet et al.   BIOCHEMICAL PHARMACOLOGY

A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models

(2010) Q Chen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes

(2010) Yunyun Su et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer

(2010) Allan Lipton et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Bioavailability Enhancement of Curcumin by Complexation with Phosphatidyl Choline

(2010) Nishant Kumar Gupta et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human    T Cells

(2009) H. Shojaei et al.   CANCER RESEARCH

A regulatory cross-talk between Vγ9Vδ2 T lymphocytes and mesenchymal stem cells

(2009) Ludovic Martinet et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Toll-Like Receptor Expression and Function in Subsets of Human γδ T Lymphocytes

(2009) K. Pietschmann et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Gemcitabine Plus Celecoxib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma

(2008) Tomislav Dragovich et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Prevention of Both Direct and Cross-Priming of Antitumor CD8+ T-Cell Responses following Overproduction of Prostaglandin E2 by Tumor Cells In vivo

(2008) M. Ahmadi et al.   CANCER RESEARCH

Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

(2008) Xuan-Fu Xu et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE